243 related articles for article (PubMed ID: 23424109)
1. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors.
Phatak SS; Zhang S
Pac Symp Biocomput; 2013; ():29-40. PubMed ID: 23424109
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
3. Predicting kinase inhibitors using bioactivity matrix derived informer sets.
Zhang H; Ericksen SS; Lee CP; Ananiev GE; Wlodarchak N; Yu P; Mitchell JC; Gitter A; Wright SJ; Hoffmann FM; Wildman SA; Newton MA
PLoS Comput Biol; 2019 Aug; 15(8):e1006813. PubMed ID: 31381559
[TBL] [Abstract][Full Text] [Related]
4. Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform.
Hudson ML; Samudrala R
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925237
[TBL] [Abstract][Full Text] [Related]
5. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
Lawrence HR; Mahajan K; Luo Y; Zhang D; Tindall N; Huseyin M; Gevariya H; Kazi S; Ozcan S; Mahajan NP; Lawrence NJ
J Med Chem; 2015 Mar; 58(6):2746-63. PubMed ID: 25699576
[TBL] [Abstract][Full Text] [Related]
6. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
7. Toward fully automated high performance computing drug discovery: a massively parallel virtual screening pipeline for docking and molecular mechanics/generalized Born surface area rescoring to improve enrichment.
Zhang X; Wong SE; Lightstone FC
J Chem Inf Model; 2014 Jan; 54(1):324-37. PubMed ID: 24358939
[TBL] [Abstract][Full Text] [Related]
8. Identification of Activated Cdc42-Associated Kinase Inhibitors as Potential Anticancer Agents Using Pharmacoinformatic Approaches.
Kumar V; Kumar R; Parate S; Danishuddin ; Lee G; Kwon M; Jeong SH; Ro HS; Lee KW; Kim SW
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830587
[TBL] [Abstract][Full Text] [Related]
9. A Computational Bipartite Graph-Based Drug Repurposing Method.
Zheng S; Ma H; Wang J; Li J
Methods Mol Biol; 2019; 1903():115-127. PubMed ID: 30547439
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
11. Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs.
Sohraby F; Aryapour H
Semin Cancer Biol; 2021 Jan; 68():249-257. PubMed ID: 32360530
[TBL] [Abstract][Full Text] [Related]
12. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
13. Applying ligands profiling using multiple extended electron distribution based field templates and feature trees similarity searching in the discovery of new generation of urea-based antineoplastic kinase inhibitors.
Dokla EM; Mahmoud AH; Elsayed MS; El-Khatib AH; Linscheid MW; Abouzid KA
PLoS One; 2012; 7(11):e49284. PubMed ID: 23185312
[TBL] [Abstract][Full Text] [Related]
14. Computational approach to the identification of novel Aurora-A inhibitors.
Morshed MN; Cho YS; Seo SH; Han KC; Yang EG; Pae AN
Bioorg Med Chem; 2011 Jan; 19(2):907-16. PubMed ID: 21194953
[TBL] [Abstract][Full Text] [Related]
15. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
Hameed R; Khan A; Khan S; Perveen S
Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
[TBL] [Abstract][Full Text] [Related]
16. Predicting drug-target interaction network using deep learning model.
You J; McLeod RD; Hu P
Comput Biol Chem; 2019 Jun; 80():90-101. PubMed ID: 30939415
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based approaches to the discovery of kinase inhibitors.
Mortenson PN; Berdini V; O'Reilly M
Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
[TBL] [Abstract][Full Text] [Related]
18. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
[TBL] [Abstract][Full Text] [Related]
20. Repurposing old drugs to fight multidrug resistant cancers.
Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
